Up 55% in October: Is Bausch Health’s turnaround just getting started?
Bausch Health (BHC) surged 55.50% in October, driven by 13 quarters of revenue and EBITDA growth. Q2 revenue hit $2.85B, up 13%, and adjusted EBITDA rose 28% to $1.075B. Management raised 2026 guidance. The stock trades at a forward P/E of 1.38x, with analysts seeing 55.8% upside to $9.90.
How this was made

The 30-second read
Why it matters
The key tradable takeaway is that the company’s latest quarter included revenue and adjusted EBITDA growth, EPS beat, and raised full-year 2026 guidance, alongside cash flow-driven net debt reduction.
Market read
For traders, the article reinforces a turnaround re-rating thesis for Bausch Health, but the magnitude of the prior run increases the importance of near-term confirmation.
What to watch
Patent-expiration risk and the sustainability of margin gains are highlighted but not quantified; traders may need to monitor debt maturity schedule and any guidance revisions after the next reporting cycle.
Background
Bausch Health has been viewed as a high-debt, legacy-overhang pharma name, but the article argues an operational turnaround is now showing sustained growth.
Ticker impact
Bausch Health shares are up 55.5% in October after Q2 results, with management raising full-year 2026 guidance across revenue, EBITDA, and cash flow.
Likely upward bias as investors re-rate the turnaround, tempered by profit-taking after a sharp month-long rally.
The article cites specific Q2 beats and guidance raises plus debt paydown, which are direct drivers of valuation and risk perception. However, it is framed as an October performance story and does not add a brand-new catalyst beyond the already-reported results.
Market effects
Supports the broader healthcare rotation into cash-flow compounders, reinforcing momentum for out-of-favor pharma turnarounds.
Primarily US-listed healthcare sentiment; limited direct regional spillover beyond US healthcare investors.
Moderate, as the turnaround includes China-related integration economics but the catalyst is US-listed company performance.
Counterpoint
The stock’s valuation and debt overhang may still cap upside if margin expansion or cash flow normalization fails after the initial turnaround phase.
Key entities
- companyBausch Health Companies Inc
Subject of the article, with Q2 results and raised 2026 guidance cited as the driver of a sharp October rally.
- personThomas Appio
CEO credited with the turnaround momentum and operational execution.

